PULCEIC develops genetic countermeasures and active radiation shielding to enable long‑duration interplanetary missions. The company builds a pipeline for space‑relevant gene therapies and multiplex gene editing, drawing on extremophile genetics to boost cellular DNA repair and resilience, while its AEGIS system actively reduces crew exposure to cosmic radiation.
Funding
Funding not disclosed
Founders
Product
Problem
Long-duration interplanetary missions expose astronauts to ionizing radiation, microgravity‑induced bone loss, muscle atrophy, and vision‑threatening neuro‑ocular changes, all of which exceed human physiological limits and increase long‑term health risks.
Solution
PULCEIC addresses these risks by developing two complementary biotechnologies. First, it creates a pipeline of space‑relevant gene therapies and multiplex gene‑editing approaches that incorporate resilience mechanisms derived from extremophile organisms, enhancing cellular DNA repair and overall tissue robustness. Second, the AEGIS system provides active radiation shielding to lower the dose of cosmic radiation reaching crew and equipment. Together, the genetic countermeasures mitigate damage from any residual radiation, while AEGIS reduces exposure at the source, enabling safer, longer human presence in deep space.
Target Audience
Primary customers are space agencies, commercial spaceflight companies, and research institutions planning long‑duration crewed missions beyond low Earth orbit.
Features
- Gene‑therapy platform targeting DNA repair pathways and cellular resilience, informed by extremophile genetics
- Multiplex genome‑editing tools to introduce multiple protective traits simultaneously
- Preclinical pipeline for validating space‑relevant genetic countermeasures against radiation, microgravity, and musculoskeletal degradation
- AEGIS active shielding technology that detects and deflects incoming cosmic particles to reduce crew dose
- Integrated approach combining upstream radiation dose reduction with downstream cellular protection